Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 5/20 | 0.53 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | NPY4R | P50391 | 9/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.48 |
| ▸ | NPY1R | P25929 | 7/20 | 0.48 |
| ▸ | NPY2R | P49146 | 5/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MC3R | P41968 | 1/20 | 0.48 |
| ▸ | MC1R | Q01726 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6552721 | 0.96 | CTSL (0.54) | MC4RCTSLNPY4RNPY5RNPY1R | |
| SCHEMBL6552897 | 0.92 | NPY4R (0.56) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL6551966 | 0.92 | NPY4R (0.56) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30029024 | 0.90 | GNPAT (0.56) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL6551485 | 0.89 | MC4R (0.57) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL6552855 | 0.89 | MC4R (0.57) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL19656447 | 0.87 | NPY4R (0.54) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30712850 | 0.86 | GNPAT (0.50) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30712847 | 0.86 | GNPAT (0.50) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30712846 | 0.86 | GNPAT (0.50) | MC4RNPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147567-A1 | Control appetites; obesity; eating disorders | TAISHO PHARMACEUTICALS CO., LTD. (JP) | 2004-07-29 | — | — | US | claimed |
| EP-1388537-A1 | ARGININE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2004-02-11 | — | — | EP | claimed |
| US-20040147567-A1 | Control appetites; obesity; eating disorders | TAISHO PHARMACEUTICALS CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1388537-A1 | ARGININE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2004-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147567-A1 | Control appetites; obesity; eating disorders | MC4R, NPY4R, MC5R | MC4R 1/4885CTSL 4034/4885NPY4R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.